Skip to content

Evaluation of effect of magnesium sulfate on reduction of cerebral vasospasm?

Comparing effect of magnesium sulfate and normal saline on intraoperative hemodynamic of patients undergoing cerebral ?aneurism surgery and rate of postoperative cerebral vasospasm?

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT2013042813159N1
Enrollment
46
Registered
2014-06-14
Start date
2014-05-25
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cerebral aneurism ?. Subarachnoid haemorrhage from intracranial artery, unspecified

Interventions

Intervention 1: Intervention group: Magnesium sulphate 50%, 20 mg/kg diluted in 100 ml of saline normal, manufactured by Pasteur Institute of Iran, during 15 minutes before infusion of anesthesia and
Treatment - Drugs
Intervention group: Magnesium sulphate 50%, 20 mg/kg diluted in 100 ml of saline normal, manufactured by Pasteur Institute of Iran, during 15 minutes before infusion of anesthesia and 10 mg/kg/hour ti
Control group: Normal Saline 0.9%, Fluid therapy During surgery according to standard procedures (Rule 4-2-1) and compensation bleeding occurs with three times of Normal Saline 0.9%

Sponsors

Vice Chancellor for Research, Mashhad University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 61 Years

Inclusion criteria

Inclusion criteria: The major inclusion criteria?:? candidate for brain aneurysm surgery after 3 days of aneurysm bleeding;? American Society of Anesthesiologists (ASA) class I and II.? The major exclusion criteria:? pathology of cardiovascular system; heart failure [Ejection fraction (EF) less than ??40%]. Previous history of hypertension; Liver or kidney diseases (impaired Liver function ?test (FT) and Glomerular filtration rate (GFR) less than 50 ml/min); Motor, ?neurological, and muscle disorders, coagulopathy [Prothrombin time (PT) more than ??16, International Normalized Ratio (INR) more than 1.5; Partial thromboplastin ?time (PTT) more than 35]; Hypomagnesaemia, More than 60 years of age;? History of allergy to any of the used medications in the experiment,? ? Overweight [Body mass index (BMI) more than 30]; Previous use of calcium channel ?blockers; Atrioventricular block.?

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Vasospasm. Timepoint: After intervention, daily. Method of measurement: Angiography and transcranial Doppler.;Mean arterial pressure. Timepoint: Before infusion, 5 minutes after infusion, every 15 minutes after infusion. Method of measurement: Arterial Line during the surgery.;Heart rate. Timepoint: Before infusion, 5 minutes after infusion, every 15 minutes after infusion. Method of measurement: Heart monitoring during the surgery.

Secondary

MeasureTime frame
Bleeding rate. Timepoint: End of surgery. Method of measurement: Based on CC of gases and suction contents.;The amount of anesthetic drugs used (propofol 2 mg/kg, fentanyl 2 mcg/kg, atracurium 0.5 mg/kg lidocaine 1.5 mg/kg). Timepoint: End of surgery. Method of measurement: Based on patient weight (kg) and Duration of Surgery.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHouman Bahar Vahdat

Ghaem Hospital

baharvahdath@mums.ac.ir+98 51 1801 2616

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026